Pharmaceutical Merger

BOSTON – Shareholders claim in a federal class action that key details are omitted from the Jan. 19 solicitation statement filed with the Securities and Exchange Commission concerning Takeda’s proposed $5.2 billion acquisition of Ariad Pharmaceuticals.